1月1日，和黄医药发布公告，以6.08亿美元（约合人民币44亿元）向金浦健服投资管理和上海医药出售上海和黄药业35%、10%的股权。交易完成后，和黄药业仅持有5%的股权，持股60%的上海医药成为上海和黄实控人。和黄医药称，交易所得款会被用在创新药研发，尤其是加注在眼下大火的ADC领域。和黄医药首个抗体靶向偶联药物（ATTC）候选药有望在今年下半年进入临床试验。2000年前后，李嘉诚旗下的和记黄埔...
Source Link1月1日，和黄医药发布公告，以6.08亿美元（约合人民币44亿元）向金浦健服投资管理和上海医药出售上海和黄药业35%、10%的股权。交易完成后，和黄药业仅持有5%的股权，持股60%的上海医药成为上海和黄实控人。和黄医药称，交易所得款会被用在创新药研发，尤其是加注在眼下大火的ADC领域。和黄医药首个抗体靶向偶联药物（ATTC）候选药有望在今年下半年进入临床试验。2000年前后，李嘉诚旗下的和记黄埔...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.